Indaptus Therapeutics, Inc. (INDP): M&A transaction — Indaptus Therapeutics change of control: David Lazar sells $11.2M stake; new CEO Junyi Dai appointed

Indaptus Therapeutics, Inc.

David Lazar sold 700K Series AAA and 196.8K Series AA Preferred shares to five purchasers for $11.2M.
Purchasers will own 96.2% of diluted shares post-conversion; may be deemed a group under Exchange Act.
Four directors resigned, including co-CEO Jeffrey Meckler; David Lazar resigned as co-CEO but remains on board.
Junyi Dai, 39, appointed CEO and Chairman; previously Managing Director at FLMD Pty Ltd and independent director.
Company to file resale registration statement within 30 days for 2.064M shares underlying Lazar's retained Series AA.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Indaptus Therapeutics, Inc. underwent a change of control involving Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng for $11,200,000 (closed 2026-03-23).

Action: change of control
Counterparty: Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng
Consideration: $11,200,000
Closing: 2026-03-23

Exact text from the filing

on March 23, 2026, David Lazar sold, in accordance with the rights afforded to Mr. Lazar in the Purchase Agreement, all of his interest and rights in the 700,000 shares of Series AAA Preferred Stock and all of his interest and rights to 196,800 shares of Series AA Preferred Stock to Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng (the “Purchasers”) in certain percentages set forth in the definitive agreements related to such transaction, for an aggregate purchase price of $11,200,000 (the “Purchase Price”).

View on SEC.gov

Browse all m&a transactions →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-012372

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.